European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Meta Expands AI Training With Employee Activity Tracking Tools 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
VANCOUVER, British Columbia, March 13, 2017 -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that management will host a conference call and audio webcast on Wednesday, March 15, 2017 at 8:30 a.m. Eastern Time to provide a business update and review preliminary fourth quarter and full year 2016 financial results.
To participate, please dial (866) 516-3002 (domestic) or (760) 298-5082 (international). A live webcast will be available in the “Investors” section of Novelion’s website, www.novelion.com, and a replay will be available for 90 days after the conclusion of the event.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the potential treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
CONTACT: Amanda Murphy, Director, Investor & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected]
